Forest Expects Namenda To Thrive Under Medicare Part D
This article was originally published in The Pink Sheet Daily
Executive Summary
Large cash-paying contingent of patients and sizable nursing home population should bring benefit from Part D coverage, company notes.
You may also be interested in...
Forest’s Namenda Gets “Not Approvable” Letter For Mild Alzheimer’s Indication
The firm blames supplementary studies – which found numerical improvement for the memantine cohort but failed to meet statistical significance – for the denial.
Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says
Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.
Nebivolol Approval Could Come In Mid-2007, Forest Says
The firm is conducting small studies of short duration after meeting with FDA regarding a May 2005 “approvable” letter.